62 /100
HIGH RISK
Score updated Jul 14, 2026

GLTO — Damora Therapeutics, Inc. Dilution Risk Tracker

Track GLTO dilution risk with DilutionWatch's stock tracker. DilutionScore™ measures dilution risk across 5 factors — lower scores indicate higher risk of share dilution.

⚠️ Not financial advice. Do your own research before making any investment decisions.

🔔 Track GLTO — Get alerts when the score changes →

As of July 14, 2026, Damora Therapeutics, Inc. (GLTO) has a DilutionWatch DilutionScore of 62/100, rated HIGH dilution risk. Damora Therapeutics, Inc. has a market capitalization of $1.73B, 61.55M shares outstanding, 67 institutional holders tracked. Key dilution vectors include approximately 179 months of cash runway.

Source: DilutionWatch (dilutionwatch.com) — data updated daily from SEC EDGAR filings. Not financial advice.

📊 Score Breakdown

📋 Offering Ability
80
💰 Cash Runway
0
📊 Float Risk
100
⚠️ Warrant Exposure
40
🔄Convertible Debt

🌦️ Dilution Forecast

☀️
Clear
No significant dilution signals
5%
📉 Score Deterioration 10%
• Score in HIGH risk zone (62/100)
🔔 Track GLTO — Get forecast alerts →

💹 Market Data

Market Cap$1.73B
Shares Outstanding61.55M
Float1.05M
Cash$568.89M
Debt$72.0K
Short InterestN/A

🏛 Institutional Holdings

67 institutional holders · 59.68M shares
#1 FMR LLC 9.05M shares
#2 Fairmount Funds Management LLC 8.71M shares
#3 Remedium Capital Partners, LLC 4.09M shares
+ 17 more holders Sign up free to view →

📉 Short Interest

Short Interest169.3K
Days to Cover6.3
% of Float16.2%
FINRA data as of Jan 15, 2026

📁 Recent SEC Activity

xbrl XBRL CONVERTIBLE Dec 31, 2020
Full SEC filing analysis available with free account

📰 Recent News

No recent news

📋 What This Means for GLTO Shareholders

Damora Therapeutics, Inc. (GLTO) has a DilutionScore of 62/100, placing it in the High dilution risk tier. This score reflects at least one active dilution mechanism — a shelf registration, ATM program, outstanding warrants, or limited cash runway — that could materially increase the share count over the next 12–18 months. Score as of July 14, 2026, updated from SEC EDGAR data.

DilutionWatch's EDGAR monitoring for GLTO shows no major active dilution programs at this time. The primary risk categories — shelf registration capacity, ATM programs, warrant overhang, and cash runway — are each within normal ranges for a company of this profile. This can change quickly if a new S-3 or Form S-1 is filed.

DilutionWatch tracks over 25 SEC filing types for GLTO in real-time, scanning EDGAR every 60 seconds. The DilutionWatch screener shows real-time score changes for GLTO alongside comparable high-risk stocks. Not financial advice — this analysis is for informational purposes only.

Track GLTO Dilution Risk in Real-Time
Get instant alerts when SEC filings impact dilution risk. Free tier available.
Start Tracking GLTO — Free
Real-time SEC alerts DilutionScore™ tracking No credit card required

🔗 Related Stocks — HIGH Risk

Other HIGH dilution risk stocks tracked by DilutionWatch with similar profiles:

Browse all 7,800+ tracked stocks →

📖 Dilution Education
→ Complete Dilution Guide for Retail Investors → Anti-Dilution Provisions Explained → Stock Dilution Red Flags to Watch → Understanding Shelf Registrations
🔬 More Research for GLTO
📊 GLTO FDA Catalyst Timeline & Biotech Grade — BiotechSigns 📡 GLTO Signal Convergence & Dark Pool Activity — StonkWhisper

Part of the Guerilla Finance research network. Cross-reference multiple data sources for better due diligence.